Leinco Technologies, Inc.
excellence in early discovery research™

Mouse CD120b (TNFR2) Antibody

Purified in vivo GOLD™ Functional Grade

Monoclonal Antibody

Product Information

Product No.:	T254
Clone:	TR75-54.7
RRID:	AB_2737570
Isotype:	Armenian Hamster IgG
Storage:	Sterile 2 to 8°C

Product Description

Specificity:
Anti-Mouse CD120 recognizes Mouse CD120. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Antigen Distribution:
Variety of cell types at low levels

Background:
Tumor necrosis factor receptor II (TNF-RII) is present on most cell types1 and is considered to play a prominent role in stimulation by TNF-alpha. TNFRII proteins are expressed by hematopoietic cells including macrophages, neutrophils, lymphocytes, thymocytes and mast cells. It is expressed by a variety of other cell types including endothelial cells, cardiac myocytes and prostate cells.2

Known Reactivity Species:
Mouse

Format:
Purified in vivo GOLD™ Functional Grade

Immunogen:
Purified Recombinant Mouse TNF R2

Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity
≥95% monomer by analytical SEC, >95% by SDS Page

Endotoxin
< 1.0 EU/mg as determined by the LAL method

Storage and Stability
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C.
Avoid Repeated Freeze Thaw Cycles.

Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Country of Origin
USA

References
1) Zuckerman, KS. et al. (1998) Cancer Res. 58:2217.
2) Sheehan, KC. et al. (1995) J. Exp. Med. 181:607.